All In Biotech

Drug Trial Radar · NCT04938583

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Mar 17, 2021

Primary completion

Oct 30, 2025

Study completion Aug 31, 2026

Sponsor

Lead sponsor
CanariaBio Inc.Industry
Sponsor type
Industry
Collaborators
Korean Cancer Study Group
First posted
Jun 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type, previously treated with 1 prior lines of therapy, and with platinum free intervals of \>6 months since last platinum-based treatment.

Conditions

  • Ovarian Cancer by FIGO Stage
  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage IV

Interventions

  • OregovomabBiological

    Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg). 2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

  • BevacizumabDrug

    15mg/Kg Day 1 (every 21 days) until progression

  • PaclitaxelDrug

    175 mg/m\^2, Day 1 x 6 cycles (every 21 days)

  • CarboplatinDrug

    AUC 5 IV Day 1 x 6 cycles (every 21 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 1cycle (21days)
  2. Efficacy based on overall response rate (ORR)Time frame: Every 6 weeks (each cycle is 21 days)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea

  • CHA Bundang Medical Center

    Seongnam-si, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Korea Anam Hospital

    Seoul, Seoul, South Korea

  • Asan Medical Hospital

    Seoul, Seoul, South Korea

  • Seoul St. Mary's Hospital

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.